NCT06236880View on ClinicalTrials.gov

A Phase 2a Study to Evaluate the Safety and Tolerability of GM-2505 in Patients With MDD

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

July 29, 2024

Study Completion Date

July 29, 2024

Conditions
Major Depressive Disorder
Interventions
DRUG

GM-2505

IV

Trial Locations (1)

Unknown

RECRUITING

MAC Clinical Research, Manchester

Sponsors
All Listed Sponsors
lead

Gilgamesh Pharmaceuticals

INDUSTRY